Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TERENCE ISAKOV

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497729222
CMS profile
339847
Location
LYNDHURST, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,902.24

117 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TERENCE ISAKOV

NPI 1497729222 · CMS profile ID 339847

Allopathic & Osteopathic Physicians / Family Medicine

LYNDHURST, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497729222?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TERENCE ISAKOV, NPI 1497729222, CMS profile ID 339847. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497729222?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TERENCE ISAKOV, NPI 1497729222, CMS profile ID 339847. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497729222?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TERENCE ISAKOV, NPI 1497729222, CMS profile ID 339847, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1497729222?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

117 matching records · $1,902.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 117 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 117.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $8.8912/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920365 CMS
Lilly USA, LLC $16.6812/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818764817 CMS
Biohaven Pharmaceuticals, Inc. $16.9912/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852524899 CMS
AbbVie Inc. $15.6512/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920361 CMS
AbbVie Inc. $12.3112/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920357 CMS
AbbVie Inc. $19.8312/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920353 CMS
Lilly USA, LLC $13.7211/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818763213 CMS
Lilly USA, LLC $18.1011/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818706643 CMS
Esperion Therapeutics, Inc. $14.5011/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838318141 CMS
Abbott Laboratories $21.7911/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815843791 CMS
Biohaven Pharmaceuticals, Inc. $21.3011/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852524895 CMS
Janssen Pharmaceuticals, Inc $12.9911/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788316903 CMS
PFIZER INC. $17.4211/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833426101 CMS
AbbVie Inc. $13.3311/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920345 CMS
AbbVie Inc. $0.6311/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920349 CMS
AbbVie Inc. $28.3211/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920341 CMS
AbbVie Inc. $15.4411/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920337 CMS
Lilly USA, LLC $19.3910/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818758239 CMS
Acerus Pharmaceuticals Corporation $12.9010/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777478843 CMS
Eyevance Pharmaceuticals LLC $12.0910/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807281929 CMS
Hikma Pharmaceuticals USA $12.0910/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 808542699 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.1510/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850007363 CMS
AbbVie Inc. $23.9410/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920333 CMS
AbbVie Inc. $10.2510/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920325 CMS
AbbVie Inc. $1.0910/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920329 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.2410/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763728370 CMS
Kowa Pharmaceuticals America, Inc. $12.3410/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805496427 CMS
AstraZeneca Pharmaceuticals LP $11.1809/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829804923 CMS
Merck Sharp & Dohme Corporation $13.4409/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848511037 CMS
Dynavax Technologies Corporation $14.7709/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800992283 CMS
SANOFI-AVENTIS U.S. LLC $19.0009/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843481979 CMS
E.R. Squibb & Sons, L.L.C. $14.4809/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783585341 CMS
GlaxoSmithKline, LLC. $12.2909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802616941 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.7409/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850363627 CMS
Sunovion Pharmaceuticals Inc. $18.1109/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821717821 CMS
AbbVie Inc. $15.4809/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920321 CMS
AbbVie Inc. $12.6509/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920317 CMS
Biohaven Pharmaceuticals, Inc. $22.4709/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852524891 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.0408/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819988715 CMS
AstraZeneca Pharmaceuticals LP $11.1208/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829572443 CMS
SANOFI-AVENTIS U.S. LLC $17.4408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843481981 CMS
AbbVie Inc. $28.7108/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920313 CMS
Esperion Therapeutics, Inc. $12.5408/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838318137 CMS
Lilly USA, LLC $17.9908/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818744089 CMS
AbbVie Inc. $15.6008/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920309 CMS
Astellas Pharma US Inc $15.4308/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821376581 CMS
PFIZER INC. $19.0008/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833454193 CMS
Teva Pharmaceuticals USA, Inc. $14.8207/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839603407 CMS
AbbVie Inc. $12.7507/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920301 CMS
AbbVie Inc. $9.7207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794920305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,522.39 107
PY2020 $879.52 54
PY2021 $1,902.24 117
PY2022 $1,778.35 103
PY2023 $1,435.31 79
PY2024 $1,667.64 89
PY2025 $975.53 53

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $3,604.05 3
PY2020 Principal investigator $85,287.08 28
PY2019 Principal investigator $244,596.18 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $863.00 12/31/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670123045
Principal investigator 1 Allergan Inc. $25,004.41 12/31/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670127117
Principal investigator 1 Allergan Inc. $11,842.70 12/16/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670112483
Principal investigator 1 Allergan Inc. $7,088.90 12/13/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670109859
Principal investigator 1 SANOFI US SERVICES INC. $1,075.00 12/12/2019 Non-covered Recipient Entity
Ohio Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691606585
Principal investigator 1 Allergan Inc. $500.00 12/09/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670107000
Principal investigator 1 Allergan Inc. $3,824.70 11/13/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670096448
Principal investigator 1 Allergan Inc. $9,972.15 11/13/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096949
Principal investigator 1 Kowa Research Institute, Inc. $500.00 11/07/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-303 No dispute reported 06/30/2026 629131175
Principal investigator 1 Allergan Inc. $17,154.15 11/05/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670094657
Principal investigator 1 Allergan Inc. $666.24 10/31/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670092873
Principal investigator 1 Kowa Research Institute, Inc. $4,640.40 10/24/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 655526279
Principal investigator 1 Allergan Inc. $3,824.70 10/22/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670089869
Principal investigator 1 Allergan Inc. $8,384.70 09/20/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670078735
Principal investigator 1 Allergan Inc. $4,092.60 09/18/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670076371
Principal investigator 1 Allergan Inc. $3,824.70 08/16/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670066783
Principal investigator 1 Allergan Inc. $5,092.00 08/16/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670066933
Principal investigator 1 Allergan Inc. $7,490.75 07/25/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670060941
Principal investigator 1 Allergan Inc. $2,406.35 07/16/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057507
Principal investigator 1 Allergan Inc. $9,122.85 06/25/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670052967
Principal investigator 1 SANOFI US SERVICES INC. $6,340.00 06/25/2019 Non-covered Recipient Entity
Ohio Clinical Research LLC
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691556031
Principal investigator 1 Allergan Inc. $660.00 06/04/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670050355
Principal investigator 1 Allergan Inc. $7,500.00 06/01/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670049831
Principal investigator 1 Allergan Inc. $157.89 05/30/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670049641
Principal investigator 1 Kowa Research Institute, Inc. $500.00 05/23/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 629123685
Principal investigator 1 Kowa Research Institute, Inc. $1,029.60 05/23/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 629123687
Principal investigator 1 SANOFI US SERVICES INC. $5,932.26 05/23/2019 Non-covered Recipient Entity
Ohio Clinical Research LLC
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691555425
Principal investigator 1 Allergan Inc. $31,719.55 05/07/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670043519
Principal investigator 1 Allergan Inc. $289.68 04/30/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041865
Principal investigator 1 Allergan Inc. $31,719.55 04/23/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670039807
Principal investigator 1 SANOFI US SERVICES INC. $341.34 04/08/2019 Non-covered Recipient Entity
Ohio Clinical Research LLC
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691556169
Principal investigator 1 SANOFI US SERVICES INC. $10,055.00 03/21/2019 Non-covered Recipient Entity
Ohio Clinical Research LLC
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691549873
Principal investigator 1 Allergan Inc. $4,509.65 02/28/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670027921
Principal investigator 1 Kowa Research Institute, Inc. $245.80 02/28/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 629123683
Principal investigator 1 Kowa Research Institute, Inc. $21.06 02/28/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-303 No dispute reported 06/30/2026 629131171
Principal investigator 1 Allergan Inc. $2,546.00 02/19/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670025639
Principal investigator 1 Kowa Research Institute, Inc. $1,782.90 02/14/2019 Non-covered Recipient Entity
Ohio Clinical Research, LLC
K-877-301 No dispute reported 06/30/2026 629123681
Principal investigator 1 Allergan Inc. $3,000.60 02/05/2019 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670022573
Principal investigator 1 Sekisui Diagnostics LLC $8,875.00 01/31/2019 Non-covered Recipient Entity
Ohio Clinical Research
A Multicenter Study Conducted to Evaluate the Performance of the OSOM ULTRA + Flu A&B Test in Point of Care Testing Sites CS-SEKFLU18-01 Version 1.0 No dispute reported 06/30/2026 692905835